China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
No risks detected for 867 from our risk checks.
China Medical System Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$13.88|
|52 Week High||HK$7.37|
|52 Week Low||HK$22.80|
|1 Month Change||-5.58%|
|3 Month Change||-32.13%|
|1 Year Change||62.34%|
|3 Year Change||32.70%|
|5 Year Change||7.10%|
|Change since IPO||361.44%|
Recent News & Updates
|867||HK Pharmaceuticals||HK Market|
Return vs Industry: 867 exceeded the Hong Kong Pharmaceuticals industry which returned -12.1% over the past year.
Return vs Market: 867 exceeded the Hong Kong Market which returned 7.3% over the past year.
Stable Share Price: 867 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 867's weekly volatility (7%) has been stable over the past year.
About the Company
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. It offers products under the direct and agency networks. The company’s products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Fundamentals Summary
|867 fundamental statistics|
Is 867 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|867 income statement (TTM)|
|Cost of Revenue||CN¥1.97b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.17|
|Net Profit Margin||37.48%|
How did 867 perform over the long term?See historical performance and comparison
4.1%Current Dividend Yield
Is China Medical System Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 867 (HK$13.88) is trading below our estimate of fair value (HK$36.67)
Significantly Below Fair Value: 867 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 867 is poor value based on its PE Ratio (9.9x) compared to the Hong Kong Pharmaceuticals industry average (9.7x).
PE vs Market: 867 is poor value based on its PE Ratio (9.9x) compared to the Hong Kong market (9.6x).
Price to Earnings Growth Ratio
PEG Ratio: 867 is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: 867 is overvalued based on its PB Ratio (2.3x) compared to the HK Pharmaceuticals industry average (1x).
How is China Medical System Holdings forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 867's forecast earnings growth (10.9% per year) is above the savings rate (1.5%).
Earnings vs Market: 867's earnings (10.9% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).
High Growth Earnings: 867's earnings are forecast to grow, but not significantly.
Revenue vs Market: 867's revenue (12.1% per year) is forecast to grow slower than the Hong Kong market (12.3% per year).
High Growth Revenue: 867's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 867's Return on Equity is forecast to be high in 3 years time (24.3%)
How has China Medical System Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 867 has high quality earnings.
Growing Profit Margin: 867's current net profit margins (37.5%) are higher than last year (33.3%).
Past Earnings Growth Analysis
Earnings Trend: 867's earnings have grown by 14.6% per year over the past 5 years.
Accelerating Growth: 867's earnings growth over the past year (39%) exceeds its 5-year average (14.6% per year).
Earnings vs Industry: 867 earnings growth over the past year (39%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 867's Return on Equity (23.5%) is considered high.
How is China Medical System Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 867's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 867's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥850.5M).
Debt to Equity History and Analysis
Debt Level: 867's debt to equity ratio (8.8%) is considered satisfactory.
Reducing Debt: 867's debt to equity ratio has reduced from 29.3% to 8.8% over the past 5 years.
Debt Coverage: 867's debt is well covered by operating cash flow (247.2%).
Interest Coverage: 867 earns more interest than it pays, so coverage of interest payments is not a concern.
What is China Medical System Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 867's dividend (4.06%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.3%).
High Dividend: 867's dividend (4.06%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.92%).
Stability and Growth of Payments
Stable Dividend: 867's dividends per share have been stable in the past 10 years.
Growing Dividend: 867's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40.1%), 867's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 867's dividends in 3 years are forecast to be well covered by earnings (33.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Kong Lam (56 yo)
Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...
CEO Compensation Analysis
Compensation vs Market: Kong's total compensation ($USD678.17K) is about average for companies of similar size in the Hong Kong market ($USD685.75K).
Compensation vs Earnings: Kong's compensation has increased by more than 20% in the past year.
Experienced Board: 867's board of directors are seasoned and experienced ( 11.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Medical System Holdings Limited's employee growth, exchange listings and data sources
- Name: China Medical System Holdings Limited
- Ticker: 867
- Exchange: SEHK
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$34.104b
- Shares outstanding: 2.46b
- Website: https://www.cms.net.cn
Number of Employees
- China Medical System Holdings Limited
- Island Place Tower
- Unit 2106
- North Point
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/28 10:06|
|End of Day Share Price||2021/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.